Cargando…

Ascorbic acid ameliorates renal injury in a murine model of contrast-induced nephropathy

BACKGROUND: Contrast induced nephropathy (CIN) is the commonest cause of iatrogenic renal injury and its incidence has increased with the advent of complex endovascular procedures. Evidence suggests that ascorbic acid (AA) has a nephroprotective effect in percutaneous coronary interventions when con...

Descripción completa

Detalles Bibliográficos
Autores principales: Rollins, K., Noorani, A., Janeckova, L., Jones, T., Griffiths, M., Baker, M. P., Boyle, J. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366137/
https://www.ncbi.nlm.nih.gov/pubmed/28340561
http://dx.doi.org/10.1186/s12882-017-0498-5
_version_ 1782517536174112768
author Rollins, K.
Noorani, A.
Janeckova, L.
Jones, T.
Griffiths, M.
Baker, M. P.
Boyle, J. R.
author_facet Rollins, K.
Noorani, A.
Janeckova, L.
Jones, T.
Griffiths, M.
Baker, M. P.
Boyle, J. R.
author_sort Rollins, K.
collection PubMed
description BACKGROUND: Contrast induced nephropathy (CIN) is the commonest cause of iatrogenic renal injury and its incidence has increased with the advent of complex endovascular procedures. Evidence suggests that ascorbic acid (AA) has a nephroprotective effect in percutaneous coronary interventions when contrast media are used. A variety of biomarkers (NGAL, NGAL:creatinine, mononuclear cell infiltration, apoptosis and RBP-4) in both the urine and kidney were assayed using a mouse model of CIN in order to determine whether AA can reduce the incidence and/or severity of renal injury. METHODS: Twenty-four BALB/c mice were divided into 4 groups. Three groups were exposed to high doses of contrast media (omnipaque) in a well-established model of CIN, and then treated with low or high dose AA or placebo (saline). CIN severity was determined by measurement of urinary neutrophil gelatinase-associated lipocalin (NGAL):creatinine at specific time intervals. Histological analysis was performed to determine the level of mononuclear inflammatory infiltration as well as immunohistochemistry to determine apoptosis in the glomeruli by staining for activated caspase-3 and DNA nicking (TUNEL assays). Reverse transcriptase PCR (rtPCR) of mRNA transcripts prepared from mRNA extracted from mouse kidneys was also performed for both lipocalin-2 (Lcn2) encoding NGAL and retinol binding protein-6 (RBP4) genes. NGAL protein expression was also confirmed by ELISA analysis of kidney lysates. RESULTS: Urinary NGAL:creatinine ratio was significantly lower at 48 h with a 44% and 62% (204.3μg/mmol versus 533.6μg/mmol, p = 0.049) reduction in the low and high dose AA groups, respectively. The reduced urinary NGAL:creatinine ratio remained low throughout the time period assessed (up to 96 h) in the high dose AA group. In support of the urinary analysis ELISA analysis of NGAL in kidney lysates also showed a 57% reduction (12,576 ng/ml versus 29,393 ng/ml) reduction in the low dose AA group. Immunohistochemistry for apoptosis demonstrated decreased TUNEL and caspase-3 expression in both low and high dose AA groups. CONCLUSIONS: Ascorbic acid reduced the frequency and severity of renal injury in this murine model of CIN. Further work is required to establish whether AA can reduce the incidence of CIN in humans undergoing endovascular procedures.
format Online
Article
Text
id pubmed-5366137
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53661372017-03-28 Ascorbic acid ameliorates renal injury in a murine model of contrast-induced nephropathy Rollins, K. Noorani, A. Janeckova, L. Jones, T. Griffiths, M. Baker, M. P. Boyle, J. R. BMC Nephrol Research Article BACKGROUND: Contrast induced nephropathy (CIN) is the commonest cause of iatrogenic renal injury and its incidence has increased with the advent of complex endovascular procedures. Evidence suggests that ascorbic acid (AA) has a nephroprotective effect in percutaneous coronary interventions when contrast media are used. A variety of biomarkers (NGAL, NGAL:creatinine, mononuclear cell infiltration, apoptosis and RBP-4) in both the urine and kidney were assayed using a mouse model of CIN in order to determine whether AA can reduce the incidence and/or severity of renal injury. METHODS: Twenty-four BALB/c mice were divided into 4 groups. Three groups were exposed to high doses of contrast media (omnipaque) in a well-established model of CIN, and then treated with low or high dose AA or placebo (saline). CIN severity was determined by measurement of urinary neutrophil gelatinase-associated lipocalin (NGAL):creatinine at specific time intervals. Histological analysis was performed to determine the level of mononuclear inflammatory infiltration as well as immunohistochemistry to determine apoptosis in the glomeruli by staining for activated caspase-3 and DNA nicking (TUNEL assays). Reverse transcriptase PCR (rtPCR) of mRNA transcripts prepared from mRNA extracted from mouse kidneys was also performed for both lipocalin-2 (Lcn2) encoding NGAL and retinol binding protein-6 (RBP4) genes. NGAL protein expression was also confirmed by ELISA analysis of kidney lysates. RESULTS: Urinary NGAL:creatinine ratio was significantly lower at 48 h with a 44% and 62% (204.3μg/mmol versus 533.6μg/mmol, p = 0.049) reduction in the low and high dose AA groups, respectively. The reduced urinary NGAL:creatinine ratio remained low throughout the time period assessed (up to 96 h) in the high dose AA group. In support of the urinary analysis ELISA analysis of NGAL in kidney lysates also showed a 57% reduction (12,576 ng/ml versus 29,393 ng/ml) reduction in the low dose AA group. Immunohistochemistry for apoptosis demonstrated decreased TUNEL and caspase-3 expression in both low and high dose AA groups. CONCLUSIONS: Ascorbic acid reduced the frequency and severity of renal injury in this murine model of CIN. Further work is required to establish whether AA can reduce the incidence of CIN in humans undergoing endovascular procedures. BioMed Central 2017-03-24 /pmc/articles/PMC5366137/ /pubmed/28340561 http://dx.doi.org/10.1186/s12882-017-0498-5 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Rollins, K.
Noorani, A.
Janeckova, L.
Jones, T.
Griffiths, M.
Baker, M. P.
Boyle, J. R.
Ascorbic acid ameliorates renal injury in a murine model of contrast-induced nephropathy
title Ascorbic acid ameliorates renal injury in a murine model of contrast-induced nephropathy
title_full Ascorbic acid ameliorates renal injury in a murine model of contrast-induced nephropathy
title_fullStr Ascorbic acid ameliorates renal injury in a murine model of contrast-induced nephropathy
title_full_unstemmed Ascorbic acid ameliorates renal injury in a murine model of contrast-induced nephropathy
title_short Ascorbic acid ameliorates renal injury in a murine model of contrast-induced nephropathy
title_sort ascorbic acid ameliorates renal injury in a murine model of contrast-induced nephropathy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5366137/
https://www.ncbi.nlm.nih.gov/pubmed/28340561
http://dx.doi.org/10.1186/s12882-017-0498-5
work_keys_str_mv AT rollinsk ascorbicacidamelioratesrenalinjuryinamurinemodelofcontrastinducednephropathy
AT noorania ascorbicacidamelioratesrenalinjuryinamurinemodelofcontrastinducednephropathy
AT janeckoval ascorbicacidamelioratesrenalinjuryinamurinemodelofcontrastinducednephropathy
AT jonest ascorbicacidamelioratesrenalinjuryinamurinemodelofcontrastinducednephropathy
AT griffithsm ascorbicacidamelioratesrenalinjuryinamurinemodelofcontrastinducednephropathy
AT bakermp ascorbicacidamelioratesrenalinjuryinamurinemodelofcontrastinducednephropathy
AT boylejr ascorbicacidamelioratesrenalinjuryinamurinemodelofcontrastinducednephropathy